Recent Updates
Recently added Catalysts
PTCT

PTC Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing...

Key Takeaway: SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET . The presentation will b

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
6.6%
average across 4 past catalysts
Lead asset
Ataluren
Phase 3 · Cystic Fibrosis

Full Press Release Details

SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET .
The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc. PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
FOR MORE INFORMATION PLEASE CONTACT:
Media: Investors:
Jane Baj Lisa Hayes
+1 (908) 912-9167 +1 (908) 868-8926
[email protected] [email protected]
Last updated: Sep 24, 2020